Loading
A phase 1/2 trial of [²¹²Pb]Pb-ADVC001 (Phase 1b) in prostate cancer, run by AdvanCell Pty Limited, now recruiting.
Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). is a phase 1/2 interventional study registered as NCT05720130 by AdvanCell Pty Limited, with 100 participants planned, started 2023-03-15 and due to reach its primary completion in 2029-01-31. Interventions recorded: [²¹²Pb]Pb-ADVC001 (Phase 1b) and [²¹²Pb]Pb-ADVC001 (Phase 2a).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/